ISPOR 2024 Home
Toggle navigation
About
News Center
Award Winners
Program
Program
Learning Formats
Plenary Sessions
Posters
Program Committee
Digital Conference Pass
Exhibits & Sponsorship
Sponsor List
Exhibitor Directory
Media Partners
Photo Gallery
ISPOR
2024
May 5-8, 2024
Home
Events
Past Conferences
ISPOR 2024
Program
Plenary Sessions
Session
A Cost-Consequence Analysis of Ponatinib Versus Imatinib in Patients with Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia in the United States
May 6, 2024, 16:30 PM
«
1541
1542
1543
(current)
1544
1545
1546
1547
1548
1549
1550
»